Business Context and Reporting Period
Daré Bioscience, Inc. (DARE) filed this Form 8-K on July 7, 2022, to report a significant non-dilutive funding event. The company is a biotechnology firm focused on developing long-acting reversible contraceptives, specifically the DARE-LARC1 program.
Key Financial Metrics
- Grant Payment Received: Approximately $7.96 million received on July 7, 2022.
- Total Funding Received to Date: Approximately $19.41 million under the Grant Agreement as of July 7, 2022.
- Total Potential Grant Value: Up to $48.95 million.
- Funding Source: Bill & Melinda Gates Foundation.
- Grant Period: June 30, 2021, to November 1, 2026.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for these metrics as this is a current report on a specific event, not a periodic financial statement.
Material Changes
The primary material change is the receipt of the $7.96 million grant payment, increasing the total non-dilutive funding received under the June 30, 2021 agreement to $19.41 million. This funding supports technology development and preclinical activities for the DARE-LARC1 program.
Outlook, Risks, and Contingencies
- Contingent Payments: Additional payments under the Grant Agreement are contingent upon the DARE-LARC1 program achieving specified development and reporting milestones during the Grant Period.
- Management Commentary: The filing confirms the funds are designated for nonclinical proof of principle studies.
- Risks: Future funding is not guaranteed and depends on milestone achievement.
Investor Verification Checklist
- Verify the specific development and reporting milestones required to unlock the remaining potential funding of approximately $29.54 million.
- Confirm the timeline for the next scheduled milestone review or payment.
- Review the company's latest 10-Q or 10-K to assess how this $7.96 million cash inflow impacts overall liquidity and cash burn rates.
- Monitor progress on the DARE-LARC1 nonclinical proof of principle studies.